Review anchor
Hepatic sodium/bile acid cotransporter
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Hepatic sodium/bile acid cotransporter
CHEMBL5287
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Hepatic sodium/bile acid cotransporter as ChEMBL target CHEMBL5287, mapped to UniProt Q14973. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5287
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q14973
Hepatic sodium/bile acid cotransporter
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Hepatic sodium/bile acid cotransporter matters
Hepatic sodium/bile acid cotransporter is reviewed as Hepatic sodium/bile acid cotransporter (UniProt Q14973); Hepatic sodium/bile acid cotransporter shows approved-linked disease relevance led by hepatitis D virus infection. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 12 approved drugs, 227 compounds, and 74 assays, with lead potency reaching pChEMBL 9.5.
Protein context
Hepatic sodium/bile acid cotransporter
Hepatic sodium/bile acid cotransporter Sequence length is 349 aa.
Review this target as Hepatic sodium/bile acid cotransporter, mapped to UniProt Q14973. Sequence length is 349 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q14973
Protein
Disease context
hepatitis D virus infection
Hepatic sodium/bile acid cotransporter shows approved-linked disease relevance led by hepatitis D virus infection. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BULEVIRTIDE ACETATE.
Start review with hepatitis D virus infection because it currently carries approved-linked support. Linked drugs include BULEVIRTIDE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 12 approved drugs, 227 compounds, and 74 assays for this target. The dominant activity type is EC50. CHEMBL4875567 is the current potency anchor at pChEMBL 9.5.
Use CHEMBL4875567 as the tractability anchor when discussing potency (pChEMBL 9.5).
Activity source · ChEMBL 36 via Core Engine
12 approved
pChEMBL 9.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Hepatic sodium/bile acid cotransporter matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q14973, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why hepatitis D virus infection is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
227
Total Compounds
74
Total Assays
12
Approved Drugs
IC50: 81.0, KI: 8.0, EC50: 138.0, KD: 1.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4875567
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL6000938
|
8.7 | EC50 | — |
|
|
No preferred name
CHEMBL5995946
|
8.7 | EC50 | — |
|
|
No preferred name
CHEMBL5931719
|
8.7 | EC50 | — |
|
|
No preferred name
CHEMBL6057770
|
8.7 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CYCLOSPORINE
CHEMBL160
|
1983 |
Source Header